Opus also announced that enrollment in the LYNX-2 pivotal Phase 3 trial, evaluating Phentolamine Ophthalmic Solution 0.75% for the treatment of visual loss in low light conditions associated with ...

FDA Fast Track Designation granted for Phentolamine Ophthalmic Solution 0.75% as treatment of significant chronic night driving impairment in keratorefractive patients with reduced mesopic vision ...

Opus Genetics (IRD) said that the FDA has granted Fast Track designation for Phentolamine Ophthalmic Solution 0.75% as a potential treatment for chronic night driving impairment and debilitating ...

The Fast Track designation is supported by the ongoing randomized, double-masked phase 3 LYNX-2 trial. The Food and Drug Administration (FDA) has granted Fast Track designation to phentolamine ...

Opus Genetics (IRD) announced completion of enrollment in the VEGA-3 Phase 3 clinical trial evaluating Phentolamine Ophthalmic Solution 0.75% for presbyopia. Opus also announced that enrollment in ...

(RTTNews) - Opus Genetics, Inc. (IRD) announced Wednesday that its Phentolamine Ophthalmic Solution 0.75 percent has been granted Fast Track designation by the U.S. FDA. This designation is for ...

Enrollment now complete in VEGA-3 pivotal Phase 3 trial evaluating Phentolamine Ophthalmic Solution 0.75% for presbyopia DURHAM, N.C., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: ...